leadf
logo-loader
viewModerna Therapeutics Inc

Moderna hit by criticism over lack of data on coronavirus vaccine candidate results

Scientists say that, based on the current available data, there is no way to prove how effective the formulation is

Moderna Therapeutics Inc - Moderna hit by criticism over lack of data on Covid-19 vaccine candidate results

Moderna Inc (NASDAQ:MRNA) was lower in premarket New York trading on Wednesday as the stock still suffers criticism over the most recent results for its coronavirus (COVID-19) vaccine candidate.

The US biotech firm published interim clinical data earlier this week saying that it reinforced its belief that its mRNA-based vaccine could prevent infections without serious side effects.

READ: Moderna announces positive interim data on Covid-19 vaccine candidate

However, according to a report published on Tuesday night by Boston Globe Media’s STAT news, some scientists believe that, based on the current available data, there is no way to prove how effective the candidate is.

STAT also pointed out that the usually vocal National Institute for Allergy and Infectious Diseases, a partner of Moderna in the project, declined to comment on the clinical data.

“It seems traders should treat every trial result with caution given the volatility around both Gilead and Moderna announcements over recent weeks,” said Josh Mahony, an analyst at IG.

“Every specialist seems to indicate that a vaccine will take some time to develop, yet markets treat each trial announcement like we are on the cusp of a huge breakthrough that could see everything swiftly return to normal.”

Shares in Moderna lost 4% to US$68.71 in premarket trading.

Quick facts: Moderna Therapeutics Inc

Price: 69.21 USD

NASDAQ:MRNA
Market: NASDAQ
Market Cap: $27.16 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Namaste releases third quarter financial numbers showing year over year...

Namaste Technologies (CVE: N-OTCMKTS: NXTTF) CEO Meni Morim joined Steve Darling from Proactive to share with viewers the company results from Q-3 2020- Morim noting an improvement in Revenue year over year and a better bottom line. Morim also told Proactive about the real bright spot for the...

16 minutes ago

2 min read